PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
Recruiting
Phase 2
Interventional Study
Breast Cancer
Residual Disease
Triple Negative Breast Cancer (TNBC)
Stage II/III
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 78 (estimated)
- Sponsor
- UNC Lineberger Comprehensive Cancer Center · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a Phase II, interventional, prospective, single-arm, multi-center study that will enroll patients with stage II/III triple negative breast cancer (TNBC) who have residual cancer burden (RCB) II/III after conventional neoadjuvant chemo-immunotherapy followed by surgery. Technological advances in ctDNA assays have improved both the sensitivity and reliability of molecular residual disease (M…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Written informed consent was obtained to participate in the study, and HIPAA authorization for the release of personal health information.
* Participant is willing and able to comply with study procedures based on the judgment of the investigator.
* Age ≥ 18 years at the time o…
Contacts